Home
Conditions
Monoclonal Gammopathy of Undetermined Significance

Clinical trial condition

Monoclonal Gammopathy of Undetermined Significance

Explore clinical trials studying Monoclonal Gammopathy of Undetermined Significance. Study availability and eligibility vary by location and protocol.

33 public trials 12 recruiting studies

Refine in advanced search Browse all conditions

Monoclonal Gammopathy of Undetermined Significance trial results

Active, not recruiting

Iceland Screens, Treats or Prevents Multiple Myeloma

NCT03327597

Conditions: Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations: University of Iceland Reykjavik, Iceland

View Trial Details

Completed

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

NCT04731844

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Genital Diseases, +27 more
Locations: University of Rochester Rochester, New York, United States

View Trial Details

Completed

Imaging in MGUS, SMM and MM

NCT01237054

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States

View Trial Details

Completed

Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery

NCT03855878

Conditions: Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations: Indiana University Simon Cancer Center Indianapolis, Indiana, United States

View Trial Details

Completed

Screening to Improve Survival in AL Amyloidosis

NCT04615572

Conditions: Amyloidosis, Blood Protein Disorders, Hematologic Diseases, +16 more
Locations: University of California, Irvine Health Chao Family Comprehensive Cancer Center Orange, California, United States

University of California, San Francisco San Francisco, California, United States

University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States

Tufts Medical Center Boston, Massachusetts, United States

View Trial Details

Completed

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

NCT03119883

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations: Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

NCT01588015

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +198 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Completed

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006

Conditions: Anemia, Anemia, Aplastic, Aplastic Anemia, +19 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Completed

Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma

NCT01955395

Conditions: Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

Massachusetts General Hospital Boston, Massachusetts, United States

View Trial Details

Completed

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

NCT00099047

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Cleveland Clinic Foundation Cleveland, Ohio, United States

View Trial Details

Monoclonal Gammopathy of Undetermined Significance

Monoclonal Gammopathy of Undetermined Significance trial results

Related conditions